Interleukin-17FT7488 allele is associated with a decreased risk of colorectal cancer and tumor progression

Nemati, Kazem; Golmoghaddam, Hossein; Hosseini, Seyed Vahid; Ghaderi, Abbas; Doroudchi, Mehrnoosh

doi:10.1016/j.gene.2015.02.014

Cited by 40 publications

(52 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Serum levels of TNFa, IL1b, IL6, IL8, and IL17A are higher in patients with colorectal cancer compared with healthy controls (39,(68)(69)(70). IL6 is additionally associated with increased tumor size, tumor stage, metastases, and decreased survival (39).…”

Section: Inflammation and Vitamin D In Patients With Colorectal Cancermentioning

confidence: 99%

“…IL17A levels also positively correlate with tumor size (70), the percentage of circulating tumor cells, and risk of recurrence (52). IL17F is, however, not detected in the serum of patients with colorectal cancer (70), whereas higher serum levels of IL8 are observed in patients with stage IV colorectal cancer compared with stage II and stage III patients (28,47). Human data on levels of IL10 and IL12 are conflicting.…”

Section: Inflammation and Vitamin D In Patients With Colorectal Cancermentioning

confidence: 99%

See 1 more Smart Citation

Vitamin D, Inflammation, and Colorectal Cancer Progression: A Review of Mechanistic Studies and Future Directions for Epidemiological Studies

Harten-Gerritsen

Balvers

Witkamp

et al. 2015

Cancer Epidemiology, Biomarkers &Amp; Prevention

View full text Add to dashboard Cite

Survival from colorectal cancer is positively associated with vitamin D status. However, whether this association is causal remains unclear. Inflammatory processes may link vitamin D to colorectal cancer survival, and therefore investigating inflammatory markers as potential mediators may be a valuable next step. This review starts with an overview of inflammatory processes suggested to be involved in colorectal cancer progression and regulated by vitamin D. Next, we provide recommendations on how to study inflammatory markers in future epidemiologic studies on vitamin D and colorectal cancer survival. Mechanistic studies have shown that calcitriol-active form of vitamin Dinfluences inflammatory processes involved in cancer progression, including the enzyme cyclooxygenase 2, the NF-kB pathway, and the expression of the cytokines TNFa, IL1b, IL6, IL8, IL17, and TGFb1. Based on this and taking into account methodologic issues, we recommend to include analysis of specific soluble peptides and proteins, such as cytokines, in future epidemiologic studies on this issue. Vitamin D and the markers should preferably be measured at multiple time points during disease progression or recovery and analyzed using mediation analysis. Including these markers in epidemiologic studies may help answer whether inflammation mediates a causal relationship between vitamin D and colorectal cancer survival. Cancer Epidemiol Biomarkers Prev; 24(12); 1820-8. Ó2015 AACR.

show abstract

Section: Inflammation and Vitamin D In Patients With Colorectal Cancermentioning

confidence: 99%

Section: Inflammation and Vitamin D In Patients With Colorectal Cancermentioning

confidence: 99%

Vitamin D, Inflammation, and Colorectal Cancer Progression: A Review of Mechanistic Studies and Future Directions for Epidemiological Studies

Harten-Gerritsen

Balvers

Witkamp

et al. 2015

Cancer Epidemiology, Biomarkers &Amp; Prevention

View full text Add to dashboard Cite

show abstract

“…It has been reported that the IL-17 rs2275913 SNP could influence the development of several kinds of cancers, such as cervical cancer, colorectal cancer, oral squamous cell carcinoma, papillary thyroid cancer, hepatocellular carcinoma, and acute myeloid leukemia (Wróbel et al, 2014;Lee et al, 2015;Li et al, 2015a,b;Nemati et al, 2015;Sun et al, 2015;Xi et al, 2015). Wróbel et al (2014) conducted a study with 62 acute myeloid leukemia patients and 125 healthy controls in a Polish population, and they found that the IL-17A rs2275913 polymorphism appeared to be correlated with susceptibility to acute myeloid leukemia.…”

Section: Discussionmentioning

confidence: 99%

“…Sun et al (2015) reported that the IL-17A rs2275913 genetic variation plays a critical role in the etiology of cervical cancer in 306 cervical cancer patients and 354 control subjects. However, Nemati et al (2015) suggested that the IL-17A rs2275913 genetic variation may reduce the risk of colorectal cancer. Xi et al (2015) assessed the association between IL-17 genetic variations and hepatocellular carcinoma with 155 patients with hepatitis B-related hepatocellular carcinoma and 171 healthy controls, and they reported that the IL-17A rs2275913 SNP did not independently contribute to this cancer.…”

Section: Discussionmentioning

confidence: 99%

IL-17 rs2275913 genetic variation contributes to the development of gastric cancer in a Chinese population

Dong

et al. 2016

Genet. Mol. Res.

View full text Add to dashboard Cite

ABSTRACT. The purpose of this hospital-based case-control study was to assess whether the interleukin (IL)-17 rs2275913 genetic variation can influence susceptibility to gastric cancer. Samples from a total of 202 gastric cancer patients and 237 controls were collected from the Linyi People's Hospital between March 2013 and March 2015. The IL-17 rs2275913 gene polymorphism was identified by polymerase chain reaction and restriction fragment length polymorphism. When compared with control subjects, gastric cancer patients were older in age (OR = 3.89, 95%CI = 2.55-5.95), male (OR = 2.08, 95%CI = 1.39-3.10), had a habit of alcohol consumption (OR = 1.71, 95%CI = 1.15-2.55), and were more likely to be infected with Helicobacter pylori (OR = 2.76, 95%CI = 1.83-4.16). We observed that the AA genotype of the IL-17 rs2275913 polymorphism resulted in a 2.32-fold risk of gastric cancer compared to the GG genotype (OR = 2.32, 95%CI = 1.20-4.54; P = 0.01). The AG combined with AA genotype of the IL-17 rs2275913 polymorphism had more risk of developing gastric cancer than the GG genotype (OR = 1.50, 95%CI = 1.01-2.23; P = 0.04). Moreover, the AA genotype of the IL-17 rs2275913 polymorphism was correlated with a higher risk of developing gastric cancer than the GG and AG genotypes combined (OR = 2.01, 95%CI = 1.08-3.79; P = 0.02). In conclusion, the results of our study suggest that the IL-17 rs2275913 polymorphism could contribute to the risk of gastric cancer.

show abstract

“…In colon cancer, these two cytokines could have in fact opposite effects since IL-17A favors cancer development and IL-17F appears to be a protective factor against tumorigenesis [18, 24]. Notably, IL-17A polymorphisms were associated with increased risk of colorectal cancer development when comparing patients to healthy controls in Iranian and Tunisian populations [25, 26]. Interestingly IL-17F polymorphisms was observed to be mainly protective in the same populations [25, 27].…”

Section: Introductionmentioning

confidence: 99%

A possible association of baseline serum IL-17A concentrations with progression-free survival of metastatic colorectal cancer patients treated with a bevacizumab-based regimen

et al. 2017

View full text Add to dashboard Cite

BackgroundColorectal cancer is a major public health issue worldwide. Interleukin-17 (IL-17) and Th17 (T-helper cell type 17)-related molecules are involved in tumor development and in resistance to bevacizumab, an anti-vascular endothelial growth factor monoclonal antibody used in association with chemotherapy in metastatic colorectal cancer. Some studies have previously shown that IL-17A and IL-17F polymorphisms, respectively rs2275913 and rs763780, are associated with gastric or colorectal cancer risk. Here we aimed at studying the influence of IL-17A-related individual factors on overall survival and progression-free survival in patients with metastatic colorectal cancer treated with a bevacizumab-based chemotherapy.MethodsPre-treatment serum biomarkers were retrospectively evaluated in 122 metastatic colorectal cancer patients treated by bevacizumab in combination with chemotherapy at 2-weeks intervals in a prospective cohort study (NCT00489697). The polymorphisms of IL-17A and IL-17F were analyzed by polymerase chain reaction - restriction fragment length polymorphism. Serum concentrations of Th17-related cytokines were measured by MultiPlex. The impact of individual parameters on overall survival and progression-free survival was assessed using multivariate Cox models.ResultsHigh baseline IL-17A serum concentrations were significantly associated with shorter progression-free survival [p = 0.043]. Other baseline serum Th17-related cytokines and polymorphisms of IL-17 were not associated with overall survival or progression-free survival.ConclusionsIn this ancillary study, baseline serum IL-17A concentration is the only Th17/IL-17 related factor that was significantly associated with the response of patients with metastatic colorectal cancer to bevacizumab. But this main significant result is highly dependent on one case which, if left out, weakens the data. Other clinical studies are required to confirm this association.Trial registration NCT00489697. June 20, 2007.

show abstract

Interleukin-17FT7488 allele is associated with a decreased risk of colorectal cancer and tumor progression

Cited by 40 publications

References 42 publications

Vitamin D, Inflammation, and Colorectal Cancer Progression: A Review of Mechanistic Studies and Future Directions for Epidemiological Studies

Vitamin D, Inflammation, and Colorectal Cancer Progression: A Review of Mechanistic Studies and Future Directions for Epidemiological Studies

IL-17 rs2275913 genetic variation contributes to the development of gastric cancer in a Chinese population

A possible association of baseline serum IL-17A concentrations with progression-free survival of metastatic colorectal cancer patients treated with a bevacizumab-based regimen

Contact Info

Product

Resources

About